Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Computer Motion (RBOT) -- Ignore unavailable to you. Want to Upgrade?

To: Volsi Mimir who wrote (728)	5/20/1999 1:29:00 AM
From: tom3Dvideo	Read Replies (2) \| Respond to of 793

Anybody out there? I just attended the annual RBOT shareholders meeting. All very positive. Major points: - AESOP has been in 60,000+ procedures, exc reliability, image among surgeons. - Hermes ramping, should see its impact esp in Q4. New alliances being developed due to technology working well and catching on. Demo showed efficacy of voice control - seamless, less people req'd in OR, shorter procedures (OR time can be $30+/minute). - ZEUS USA development proceeding well - 10 stage 1 patient trials completed, should know in ~10 days from FDA re stage 2. - More big name hospitals getting Zeus - Mass Gen, Duke U, ... Numerous surgeons being trained, programs at all site hospitals progressing. - ZEUS app'd in Europe, 7 sites currently being trained, developing protocols. MDT assisting there (They have Euro dist agreement). - New ZEUS instruments show articulation ("wrist") right at instrument tip inside patient. I believe this used to be one of Intuitive's former advantages over ZEUS. - Intuitive design very large, obtrusive, doesn't allow asst surgeons to participate at the patient as ZEUS does. Intuitive generally believed to be behind. - Expect profitability end of CY2000. Steady yr-yr rev increases expected to continue. - Cardio stocks generally down due to inflated, unrealized values of a few (Heartport?). Back to "show me", though with RBOT's revenue record that is happening well. All in all it seemed like excellent progress on all fronts. RBOT is a screaming buy at this price. Back up the truck.